New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2014
07:03 EDTINCY, LLY, NVSIncyte sees FY14 Jakafi net product revenues $315M-$335M
The company (INCY) expects to receive a $60M milestone payment under its collaboration agreement with Novartis (NVS) when European Union pricing approval for Jakavi is received in a third major European country. Excluding any other potential milestones received under collaborations, the company expects revenues of approximately $13M from the amortization of the upfront payments received under its collaboration agreement with Lilly (LLY). The company expects interest expense to be approximately $48M, including a non-cash expense of $37M related to the amortization of the discount on the 2015 Notes, 2018 Notes and 2020 Notes.
News For INCY;NVS;LLY From The Last 14 Days
Check below for free stories on INCY;NVS;LLY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 8, 2014
11:03 EDTLLYPiper Jaffray's biopharm analyst holds an analyst/industry conference call
Biopharm Analyst Schimmer discusses PCSK9 Inhibitors and other atherosclerosis approaches on an Analyst/Industry conference call. Relevant companies AEGR, ALNY, AMGN, ARNA, AZN, BMY, CBST, LLY, ESPR, GSK, ICPT, ISIS, MNKD, MRK, OREX, PFE, REGN, RHHBY, SNY and VVUS may be included on the Analyst/Industry conference call to be held on April 10 at 3 pm.
10:03 EDTLLYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:21 EDTLLYEli Lilly to challenge verdict in Terrence Allen, et al. v. Takeda case
Subscribe for More Information
08:39 EDTLLYTakeda to challenge award of $6B in punitive damages, Lilly ordered to pay $3B
Takeda Pharmaceuticals (TKPYY) announced last night that in the case of Terrence Allen, et al. v. Takeda Pharmaceuticals North America the jury found in favor of the plaintiffs and awarded $1.475M in compensatory damages. The allocation of liability was 75% Takeda and 25% Eli Lilly (LLY). The jury also awarded $6B in punitive damages from Takeda and $3B from co-defendant, Eli Lilly. “Takeda respectfully disagrees with the verdict and we intend to vigorously challenge this outcome through all available legal means, including possible post-trial motions and an appeal. We have empathy for the Allens, but we believe the evidence did not support a finding that ACTOS caused his bladder cancer. We also believe we demonstrated that Takeda acted responsibly with regard to ACTOS,” said Kenneth Greisman, senior vice president, general counsel, Takeda. Reference Link
08:26 EDTLLYEli Lilly upgraded at BMO Capital
Subscribe for More Information
07:22 EDTNVSCaSA-ISPE to hold a conference
21st Annual Lilfe Sciences Technology Conference is being held in Raleigh, North Carolina on April 8.
06:24 EDTLLYEli Lilly upgraded to Market Perform from Underperform at BMO Capital
Subscribe for More Information
April 7, 2014
07:27 EDTNVSAmerican Association of Cancer Research to hold annual meeting
Subscribe for More Information
05:32 EDTNVSNovartis Bexsero vaccine receives FDA Breakthrough Therapy designation
Novartis announced that Bexsero, Meningococcal Group B Vaccine, has received a Breakthrough Therapy designation from the FDA. Bexsero is already approved in Europe, Canada and Australia to help protect against invasive meningococcal disease caused by serogroup B. Novartis plans to file for U.S. licensure of Bexsero as early as Q2; exact timing will depend on guidance from the FDA. This is the fourth Breakthrough Therapy designation for Novartis, underscoring leadership in developing innovative therapies and vaccines. This announcement comes on the heels of a landmark decision from regulators in the UK, where the Joint Committee on Vaccination and Immunisation recommended the inclusion of Bexsero in the country's National Immunisation Programme for routine use in infants from two months of age.
April 6, 2014
13:57 EDTLLYLilly to present data from bemaciclib as potential treatment for breast cancer
Subscribe for More Information
April 3, 2014
10:00 EDTLLYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:51 EDTLLYEli Lilly upgraded at Cowen
As reported previously, Cowen raised its rating on Eli Lilly to Outperform from Neutral. The firm cited its Alimta patent victory, margin expansion potential, and late stage pipeline catalysts for the upgrade. Price target raised to $68 from $61.
08:27 EDTLLYLeerink's biotech analyst holds a dinner meeting update
Biotech Analyst Liang holds an update from the AACR's Annual Meeting to discuss some of the presentations including PFE/AMGN's Palbociclib, PBYI/PFE's Neratinib, as well as other new agents for breast cancer from LLY, MDVN and CLDX, in San Diego on April 7 at 9 pm.
08:06 EDTNVSApricus Biosciences granted national phase approval for Vitaros in Luxembourg
Apricus Biosciences (APRI) announced that the Ministry of Health of Luxembourg has granted national phase approval to Vitaros, Apricus' novel topical on-demand treatment for erectile dysfunction. The company has now received a total of nine national phase approvals for Vitaros®, including Luxembourg, Belgium, France, Germany, Ireland, Italy, the Netherlands, Sweden and the United Kingdom following its broad approval by European health authorities in June 2013. Apricus has an exclusive commercialization partnership in place with Hexal AG, an affiliate within the Sandoz Division of the Novartis (NVS), for the commercialization of Vitaros in several European countries, including Luxembourg.
06:33 EDTLLYEli Lilly upgraded to Outperform from Market Perform at Cowen
Subscribe for More Information
06:26 EDTNVSNovartis placing temporary moratorium on all IIT funding in Japan
Subscribe for More Information
06:26 EDTNVSNovartis announces third-party internal review of IITs
06:25 EDTNVSNovartis appoints Dirk Koshce as head of Novartis Pharmaceuticals
Subscribe for More Information
05:31 EDTNVSNovartis says data on 19 investigational compounds to be presented
Novartis announced that early stage data on 19 investigational compounds in its oncology pipeline will be presented at the annual meeting of the American Association of Cancer Research. Among the data being presented are single agent and combination studies with key investigational compounds in the Novartis Oncology breast cancer development program, including an early phase study of the CDK4/6 inhibitor LEE011 and PI3K inhibitors BKM120 and BYL719. LEE011 and BKM120 are currently in Phase III and BYL719 is in Phase I trials for the treatment of advanced breast cancer.
April 2, 2014
06:34 EDTNVSNovartis price target raised to $93 from $88 at Leerink
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use